The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)

M.Al Ghobain, F. Rebh, Saad A.,A.H. Khan,N. Mehyar, A. Mashhour,I. Islam, Y. Alobaida,A.S. Alaskar,M. Boudjelal, M.Al Jeraisy

Journal of Infection and Public Health（2022）

引用 2|浏览2

暂无评分

摘要

Among adult patients hospitalized with COVID-19 pneumonia, the treatment with Zafirlukast, compared to placebo, did not significantly improve symptoms resolution.

查看译文

关键词

COVID-19,Coronavirus,Zafirlukast,Randomized clinical trial,SARS-CoV-2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要